Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
9
×
boston blog main
clinical trials
9
×
life sciences
national blog main
boston top stories
rna interference
national top stories
new york blog main
new york top stories
fda
amgen
biotech
boston
regeneron pharmaceuticals
deals
drugs
inclisiran
new york
patisiran
pcsk9 inhibitors
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
alexion pharmaceuticals
alirocumab
aminolevulinic acid
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
evolocumab
givosiran
hepatitis b
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
national
novartis
What
drug
9
×
fda
pharmaceuticals
alnylam
medicines
new
cholesterol
market
medco
medicine
rna
rnai
bio
brings
data
gene
interference
long
lowering
ok
patients
roundup
second
seek
speedy
acquire
advantages
afternoon
ago
agreed
alnylam’s
approval
approved
aren’t
bar
based
billion
bringing
cash
caught
Language
unset
Current search:
drug
×
" clinical trials "
×
" alnylam pharmaceuticals "
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More